NCT02733029 is a Phase 2 clinical trial of Sonazoid in Renal Transplant Rejection, sponsored by Brigham and Women's Hospital.

Who is sponsoring NCT02733029?

NCT02733029 is sponsored by Brigham and Women's Hospital.

What drugs are being tested in NCT02733029?

Interventions in NCT02733029: Sonazoid, contrast enhanced ultrasonography.

What condition does NCT02733029 study?

NCT02733029 studies Renal Transplant Rejection.

Is NCT02733029 still recruiting?

NCT02733029 is currently completed. Last updated 6 March 2023.

Last reviewed 2023-03-06 · How we verify

NCT02733029

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection

Completed Phase 2 Last updated 6 March 2023

What this trial tests

Phase 2 trial testing Sonazoid in Renal Transplant Rejection in 8 participants. Completed in 1 February 2023.

Timeline

30 May 2018

Primary endpoint
30 May 2022

1 February 2023

Quick facts

Lead sponsor	Brigham and Women's Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	8
Start date	30 May 2018
Primary completion	30 May 2022
Estimated completion	1 February 2023
Sites	1 location across United States

Drugs / interventions tested

Sonazoid
contrast enhanced ultrasonography — full drug profile →

Conditions studied

Renal Transplant Rejection — all drugs for Renal Transplant Rejection →

Sponsor

Brigham and Women's Hospital

Who can join

Adults 18 to 75, any sex, with Renal Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the feasibility and efficacy of detecting kidney transplant rejection using contrast enhance ultrasonography with the contrast agent Sonazoid.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evolving Medical Imaging Techniques for the Assessment of Delayed Graft Function: A Narrative Review.
Hysi E, Kaur H, Young A. · · 2021 · cited 3× · PMID 34707880 · DOI 10.1177/20543581211048341

Verify or expand the search:

Other trials of Sonazoid

Trials testing the same drug.

NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting
NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
NCT03245255 — Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound · Phase 2 · completed
NCT02968680 — Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma · Phase 1 · terminated

Other recruiting trials for Renal Transplant Rejection

Currently open trials in the same condition.

NCT03991780 — Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection · Phase 1, PHASE2 · active not recruiting
NCT03719339 — VIRTUUS Children's Study · active not recruiting

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02733029 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 6 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02733029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing